

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣藥業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1681)

**POLL RESULTS OF THE ANNUAL GENERAL MEETING
HELD ON WEDNESDAY, 31 MAY 2017**

The board of directors of the Company (the “**Board**”) is pleased to announce that, at the AGM held on 31 May 2017, all the resolutions proposed were passed by the shareholders of the Company.

Reference is made to the circular of Consun Pharmaceutical Group Limited (the “**Company**”) dated 28 April 2017 (the “**Circular**”) and the notice of the annual general meeting (the “**AGM**”) dated 28 April 2017. Terms used in this announcement shall have the same meaning as those defined in the Circular unless the context requires otherwise.

The Board is pleased to announce that, at the AGM held on Wednesday, 31 May 2017, all proposed resolutions as set out in the notice of AGM dated 28 April 2017 were passed by way of poll.

As at the date of the AGM, the total number of issued Shares of the Company was 828,127,800 Shares, which was the total number of Shares entitling the holders to attend and vote on the resolutions at the AGM. There were no Shares entitling the holders to attend and abstain from voting in favour of the resolutions at the AGM. No Shareholders are required to abstain from voting at the AGM. The total number of Shares held by the Shareholders or their proxy(ies) who have attended the AGM and are entitled to vote is 443,614,468 Shares, representing approximately 53.57% of the total number of issued Shares of the Company as at the date of this announcement.

The poll results in respect of the resolutions are as follows:

Ordinary resolutions		Number of votes cast and approximate percentage of total number of votes cast	
		For	Against
1.	To receive and approve the audited consolidated financial statements together with the directors’ report and the independent auditor’s report of the Company for the year ended 31 December 2016.	439,014,468 (98.96%)	4,600,000 (1.04%)
2.	(a) To re-elect Mr. AN Yubao as an executive director of the Company.	438,887,468 (98.93%)	4,727,000 (1.07%)
	(b) To re-elect Professor ZHU Quan as an executive director of the Company.	438,036,468 (98.74%)	5,578,000 (1.26%)
	(c) To authorise the board of directors of the Company to fix their remuneration.	439,014,468 (98.96%)	4,600,000 (1.04%)

Ordinary resolutions		Number of votes cast and approximate percentage of total number of votes cast	
		For	Against
3.	To declare and pay to the shareholders of the Company a final dividend of HK\$0.05 per ordinary share of the Company for the year ended 31 December 2016.	443,614,468 (100%)	0 (0%)
4.	To re-appoint KPMG as the auditors of the Company and to authorize the board of directors to fix their remuneration.	438,961,468 (98.95%)	4,653,000 (1.05%)
5.	To grant a general and unconditional mandate to the directors of the Company to allot, issue and deal with the additional ordinary shares of the Company with the total number of shares not exceeding 20% of the total number of the issued shares of the Company.	395,885,130 (89.24%)	47,729,338 (10.76%)
6.	To grant a general and unconditional mandate to the directors of the Company to repurchase shares of the Company with the total number of shares not exceeding 10% of the total number of the issued shares of the Company.	439,014,468 (98.96%)	4,600,000 (1.04%)
7.	To extend the general and unconditional mandate granted to the directors of the Company to issue, allot and deal with additional shares of the Company under resolution numbered 5 to include the number of shares of the Company repurchased pursuant to the general and unconditional mandate to repurchase shares under resolution numbered 6.	396,840,729 (89.46%)	46,773,739 (10.54%)

As more than 50% of the votes were cast in favour of each of the above resolutions, all such resolutions were duly passed by the shareholders of the Company as ordinary resolutions by way of poll. The Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking.

By Order of the Board
Consun Pharmaceutical Group Limited
An Yubao
Chairman

Hong Kong, 31 May 2017

As of the date of this announcement, the board of directors of the Company comprises Mr. AN Yubao, Ms. LI Qian and Professor ZHU Quan as executive directors; Mr. LIN Sheng as non-executive director; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHENG Xinxin as independent non-executive directors.